Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by pericles1on Jul 08, 2011 9:59pm

265 Views

Post# 18813343

RE: RE: RE: RE: Patience and Persistance

Excellent sharkfood, I agree but my expectations were quite high. I hoped for over 40% CR and PR with a least one CR. I have high expectations for Squamous cell, if that trial is as disappointing as this then I will really be in the dumps. Brad can spin it all he wants but I predict they will not proceed with a new trial in NSCLC, it will be in Squamous cell.

I think head and neck will be approved but this sure puts a chill on the stock for the moment.

Bullboard Posts

Gold vs. bitcoin, where should you invest?